Voyager Therapeutics’ (VYGR) “Positive” Rating Reaffirmed at Wedbush
Voyager Therapeutics, Inc. (NASDAQ:VYGR)‘s stock had its “positive” rating reiterated by analysts at Wedbush in a research note issued to investors on Tuesday. They presently have a $31.00 price target on the stock, down from their prior price target of $36.00. Wedbush’s price objective indicates a potential upside of 36.20% from the stock’s previous close.
VYGR has been the topic of a number of other research reports. ValuEngine lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Raymond James Financial, Inc. began coverage on Voyager Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target on the stock. Robert W. Baird began coverage on Voyager Therapeutics in a research report on Monday. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $28.44.
Voyager Therapeutics (NASDAQ:VYGR) opened at 22.73 on Tuesday. The stock’s market cap is $611.51 million. The firm has a 50-day moving average price of $19.97 and a 200 day moving average price of $12.28. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. On average, equities research analysts anticipate that Voyager Therapeutics will post ($2.89) EPS for the current fiscal year.
In other news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. Following the sale, the insider now owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 32,940 shares of company stock worth $490,092 in the last three months. Corporate insiders own 8.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of VYGR. DAFNA Capital Management LLC raised its position in shares of Voyager Therapeutics by 187.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after acquiring an additional 133,488 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Voyager Therapeutics by 232.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock worth $879,000 after acquiring an additional 68,574 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $1,122,000. HarbourVest Partners LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth about $400,000. Finally, Northern Trust Corp raised its position in shares of Voyager Therapeutics by 26.8% during the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after acquiring an additional 28,222 shares in the last quarter. 40.72% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.